Reuters logo
Ipsen says to seek approval for muscle-spasm drug
February 5, 2014 / 6:15 AM / 4 years ago

Ipsen says to seek approval for muscle-spasm drug

PARIS, Feb 5 (Reuters) - French drugmaker Ipsen said that it would begin the process of regulatory approval for a muscle-spasm drug, branded Dysport Next Generation, after a liquid-toxin trial showed it was “safe and efficacious”.

“On the basis of these results and feedback from the principal investigator of the Phase III study, Ipsen intends to initiate a dialogue with key agencies on the regulatory approach to file the first ready-to-use liquid toxin A in Europe and rest-of-world,” Ipsen said. (Reporting by Lionel Laurent)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below